Duvelisib Posters

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO trial

Presenter: Jennifer Brown, Dana-Farber Cancer Institute

Presented at the 61st ASH Annual Meeting | Orlando, FL | December 7 – 10, 2019

Publication ID: 4312
Session: 642. CLL: Therapy, excluding Transplantation: Poster III

Location: Orange County Convention Center, Poster Hall
Date and Time: Monday, December 9, 2019, 6:00 – 8:00 pm ET

 

 

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 PRIMO Trial: Selection of Regimen for the Dose-Expansion Phase

Presenter: Steven Horwitz, Memorial Sloan Kettering Cancer Center

Presented at the 61st ASH Annual Meeting | Orlando, FL | December 7 – 10, 2019

Publication ID: 1567
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Location: Orange County Convention Center, Poster Hall B
Date and Time: Saturday, December 7, 2019, 5:30 – 7:30 pm ET

 

Dual PI3K-Delta/Gamma Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Presenter: Andrea Iannello | Università degli Studi di Torino

Presented at the 61st ASH Annual Meeting | Orlando, FL | December 7 – 10, 2019

Publication ID: 3146
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II

Location: Orange County Convention Center, Poster Hall B
Date and Time: Sunday, December 8, 2019, 6:00 – 8:00 pm ET

* Verastem Preclinical Collaboration

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL

Presenter: Jennifer Crombie, Dana-Farber Cancer Institute

Presented at the 61st ASH Annual Meeting | Orlando, FL | December 7 – 10, 2019

Location: Orange County Convention Center, Poster Hall
Date and Time: Saturday, December 7, 2019, 5:30 – 7:30 pm ET

* Verastem-supported Investigator-Sponsored Trial

 

Patterns of duvelisib-induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high-risk factors treated in the DUO trial

Jacqueline Barrientos, Ian Flinn, Matthew Davids, Amanda Cashen, Nicholas Chiorazzi, Shih-Shih Chen, Samantha Hidy, Jonathan Pachter, Stephanie Lustgarten, David Weaver, Jennifer R. Brown
Presented at the 7th Annual meeting of the Society of Hematologic Oncology (SOHO) | Houston, TX 

Date: September 11-14, 2019

Duvelisib Presentations

Duvelisib, an oral dual PI3K-δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: rationale for the Phase 2 PRIMO trial

Steven Horwitz, M.D., Memorial Sloan Kettering Cancer Center
Presented at the 15th International Conference on Malignant Lymphoma (ICML) | Lugano, Switzerland | June 18-22, 2019

Location: Auditorium (USI Universita)
Date and Time: Wednesday, June 19, 2019, 5:05 – 6:05 pm

The Combination of Duvelisib, a PI3Kδ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Steven M. Horwitz MD, Alison J. Moskowitz MD, Eric D Jacobsen MD, Neha MehtaShah MD, Michael S Khodadoust MD, PhD, David C. Fisher MD PhD, Patricia Myskowski MD, Erica B.K. Wang MD, Marianne Tawa RN MSN ANP, Theresa Davey MMSc PAC, William Blouin MBA, Helen Hancock NP, Nivetha Ganesan MPH, Natasha Galasso BA, Evan Marzouk BA, Alexandra Bahgat BS, Hallie Jester BA, Sophia Fong BS, Abeer Butt BS, Ahmet Dogan MD PhD, Youn H. Kim MD and David M Weinstock MD
Presented at the 60th American Society of Hematology (ASH) Annual Meeting | San Diego, California, USA | December 1-4, 2018

Preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-delta,gamma inhibitor, duvelisib, in combination with rituximab or obinutuzumab

Carla Casulo, M.D., Assistant Professor, Wilmot Cancer Institute, University of Rochester
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 pm PT

DYNAMO: A Phase 2 Study of Duvelisib in Patients with Refractory Indolent Non-Hodgkin Lymphoma

Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt, Z Nagy, O Tournilhac, KE Abou-Nassar, M Crump, ED Jacobsen, S de Vos, P Santabarbara, W Shi, L Steelman, ND Wagner-Johnston
December 05, 2016

American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 5, 2016, 6:15 pm PT

Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma

June 16, 2017

Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma

88% of Patients had a Reduction in the Size of Target Lymph Nodes

Duvelisib Remains Well-Tolerated in Long-Term Follow Up

Defactinib Posters

Phase I Study of Defactinib Combined with Pembrolizumab and Gemcitabine in Advanced Cancer

Andrea Wang-Gillam, A. Craig Lockhart, Benjamin Tan, Rama Suresh, Kian-Huat Lim, Lee Ratner, Ashely Morton, Jess Huffman, Samantha Marquez, Nicolas Boice, David G DeNardo
Presented at the 2018 American Society for Clinical Oncology Annual Meeting | Chicago, Illinois, USA | June 1-5, 2018

An Alternative Splicing Signature that Identifies Breast Cancer Stem Cells

Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting

The Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function in vitro and Tumorigenicity in Mice

Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting

The FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function in vitro and Tumor Growth in vivo

Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting

Gene Expression and Alternative Splicing Signatures Discriminate Breast Cancer Stem Cells from Fibroblasts

David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology

Defactinib Presentations

iMig 2014: Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM

Raphael Bueno1, Ritu R Gill1, Julianne Barlow1, David M Jackman1, Beow Y Yeap1, David Weaver2, Mahesh Padval2, Rachel Sorensen2, Mitchell Keegan2
October 23, 2014
iMig, Cape Town October 2014

  1. Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA
iMig 2014: FAK Inhibitor VS-6063 (defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy

Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014

WCLC 2015: The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma

Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Development, Verastem, Inc.